Please login to the form below

Not currently logged in
Email:
Password:

PARP inihibitor

This page shows the latest PARP inihibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Meanwhile, Pfizer’s drug will also have to compete with two

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Medscape Medical Affairs

Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....